




The Brazilian Journal of INFECTIOUS DISEASES

www.elsevier.com/locate/bjid



Letter to the Editor

How we can utilize the Xpert MTB/RIF assay to decide on airborne infection isolation of inpatients with tuberculosis suspicion in Brazil: a brief review of the current data



Dear Editor,

Nowadays, for prevention of tuberculosis (TB) transmission at health care facilities, the patient with a presumptive diagnosis of infectious active TB requires airborne infection isolation (AII) until three negative respiratory specimens 8–24 h apart (acid-fast bacilli strategy). However, with the current use of rapid molecular assay, Xpert MTB/RIF assay[®] (Xpert, Cepheid, Sunnyvale, California), an update of this recommendation is necessary. Few studies have addressed this specific issue, the majority of them performed in the United States. In a study using a decision analysis model, associated with primary data on costs and outcomes, the Xpert MTB/RIF assay to guide triage of inpatients with presumed pulmonary TB observed a cost reduction of AII by \$2278 per inpatient admission.¹ Another observational cohort study with 207 inpatients demonstrated that all strategies based on Xpert resulted on reduction of AII duration when compared with AFB management.² In a prospective observational study, including 142 admissions, the comparison between serial sputum microscopy and a single Xpert MTB/RIF for triage of patients for AII, resulted in identical sensitivity and negative predictive value, 89% and 99%, respectively.³ The clinical trial “ACTG A5295/TBTC 34” showed that one or two Xpert MTB/RIF assay were each significantly more sensitive and specific than three AFB smears for identifying culture positive patients.⁴ In February 2015, based on an independent analysis of “ACTG A5295/TBTC 34”, the US Food Drug and Administration approved the expansion the Xpert MTB/RIF assay for AII definition in the United States based on the negative predictive value of one or two specimen Xpert strategy for absence of MTB-complex on AFB smears were 99.7% and 100%, respectively.⁵ To date we are not aware of specific published recommendation of Xpert-strategy for AII definition in Brazil. The data herein briefly reviewed is indicative of the approach

of using one or two Xpert MTB/RIF to replace the AFB strategy for discontinuation of airborne infection isolation of patients with presumed pulmonary TB at Brazilian health care facilities.

Conflicts of interest

The author declares no conflicts of interest.

REFERENCES

- Millman AJ, Dowdy DW, Miller CR, et al. Rapid molecular testing for TB to guide respiratory isolation in the U.S.: a cost-benefit analysis. *PLOS ONE*. 2013;8:e79669.
- Lippincott CK, Miller MB, Popowich EB, Hanrahan CF, Van Rie A. Xpert MTB/RIF Assay shortens airborne isolation for hospitalized patients with presumptive tuberculosis in the United States. *Clin Infect Dis*. 2014;59:186–92.
- Chaisson LH, Roemer M, Cantu D, et al. Impact of GeneXpert MTB/RIF assay on triage of respiratory isolation rooms for inpatients with presumed tuberculosis: a hypothetical trial. *Clin Infect Dis*. 2014;59:1353–60.
- Luetkemeyer AF, Firnhaber C, Kendall MA, et al. Xpert MTB/RIF Versus AFB Smear to Determine Respiratory Isolation of US TB Suspect. Abstract Number 824. CROI February 23–26, Seattle, Washington; 2015 <http://www.croiconference.org/sessions/xpert-mtb/rif-versus-afb-smear-determine-respiratory-isolation-us-tb-suspects> [accessed 14.09.15].
- Division of Microbiology Devices, Office of In Vitro Diagnostics and Radiological Health, Center for Devices and Radiological Health, Food and Drug Administration, Centers for Disease Control and Prevention (CDC). Revised device labeling for the Cepheid Xpert MTB/RIF assay for detecting *Mycobacterium tuberculosis*. *MMWR Morb Mortal Wkly Rep*. 2015;64:193.

Mariângela Ribeiro Resende*

Discipline of Infectious Diseases at the Department of Internal Medicine, Faculdade de Ciências Médicas, Universidade Estadual de Campinas, Campinas, SP, Brazil

*Correspondence to: Infectious Diseases, Faculty of Medical Sciences, State University of Campinas, Tessália Vieira de

Camargo, 126. Cidade Universitária – Barão Geraldo Campinas, SP 13083970, Brazil.

E-mail address: mresende@fcm.unicamp.br

Received 18 September 2015

Accepted 26 September 2015

Available online 25 November 2015

1413-8670/© 2015 Elsevier Editora Ltda. All rights reserved.

<http://dx.doi.org/10.1016/j.bjid.2015.09.010>